[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100424455":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":44,"centralContacts":49,"locations":54,"responsibleParty":72,"collaborators":74,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":10,"eligibilityCriteria":82,"healthyVolunteers":79,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"ICI-pneumonitis",null,"Cancer patients experiencing ICI-pneumonitis",[13],"Drug: Immune checkpoint blockade",{"label":15,"type":10,"description":16,"interventionNames":17},"Radiotherapy induced pneumonitis","Cancer patients experiencing RT-pneumonitis",[18],"Radiation: Radiotherapy",{"label":20,"type":10,"description":21,"interventionNames":22},"TKI-induced pneumonitis","Cancer patients experiencing TKI-induced pneumonitis",[23],"Drug: Targeted therapy",[25,33,39],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Immune checkpoint blockade","ICI, administered as standard-of-care treatment",[9],[31,32],"Pembrolizumab","Durvalumab",{"type":26,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Targeted therapy","TKI, administered as standard-of-care treatment",[20],[38],"TKI",{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":10},"RADIATION","Radiotherapy","RT, administered as standard-of-care treatment",[15],[45],{"name":46,"affiliation":47,"role":48},"Els Wauters, MD, PhD","University Hospitals - KU Leuven","PRINCIPAL_INVESTIGATOR",[50],{"name":46,"role":51,"phone":52,"phoneExt":10,"email":53},"CONTACT","+3216340942","els.wauters@uzleuven.be",[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Universitaire Ziekenhuizen Leuven","RECRUITING","Leuven","Flemish Brabant","3000","Belgium","BE",{"type":64,"coordinates":65},"Point",[66,67],4.70093,50.87959,{"lat":67,"lon":66},[70],{"name":46,"role":51,"phone":71,"phoneExt":10,"email":53},"016340942",{"type":73,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[75],{"name":76,"class":6},"KU Leuven","100424455","a-single-cell-approach-to-identify-biomarkers-of-pulmonary-toxicity-for-immune-checkpoint-blockade-100424455",false,"NCT04807127","A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade","Inclusion criteria:\n\n* Adult M\u002FF\u002FX (\\>= 18 years)\n* Patients receiving or having received treatment per guidelines\n* Patients undergoing bronchoscopy with BAL, for possible cancer treatment-induced pneumonitis\n* Not included in other clinical trials\n* Signed informed consent form\n\nExclusion criteria:\n\n• Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and\u002For bio-informatician, specialized in single-cell analysis.","ALL","18 Years","120 Years",{"count":87,"type":88},60,"ESTIMATED","OBSERVATIONAL","The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer patients experiencing cancer therapy-induced pneumonitis on a single-cell scale. These mechanistic insights can directly lead to putative diagnostic biomarkers and therapeutic targets.\n\nA second highly clinically relevant hypothesis is that single-cell profiling of blood samples will reveal circulating biomarkers of ICB toxicity, making non-invasive diagnosis feasible.",[92,93,94],"Pneumonitis, Interstitial","Immunotherapy","Immune-related Adverse Events","2024-06-28",{"date":97,"type":98},"2024-07-01","ACTUAL",{"date":100,"type":98},"2020-02-01",{"date":102,"type":88},"2025-01-31",{"name":5,"class":6},1]